Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06635889 · ClinicalTrials.gov registry record · Phase 2
Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain
A Phase 2 study of Nephrolithiasis, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
- 1
- Study location
NCT06635889: Recruiting Phase 2 study of Nephrolithiasis, sponsored by University of Chicago.
NCT06635889 is a Phase 2 study of Nephrolithiasis that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 116 participants, roughly in line with the 117-participant average among 16 other Nephrolithiasis trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06635889, a Phase 2 study of Nephrolithiasis, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
- 1
- Study location
Study Summary
Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the effect of instilling bupivacaine in the bladder following ureteroscopy. This is a randomized study that will investigate the effect of instilling bupivacaine in the bladder following routine ureteroscopy, laser lithotripsy and ureteral stenting in the treatment of stone disease. Compared to a placebo of Normal Saline, our study hypothesizes that administration of topical bupivacaine in the bladder will decrease post-operative pain and lower urinary tract symptoms while improving quality of life in the early post-operative period.
Primary Outcome
Pain will be assessed using a Likert 10-point scale upon emergence from anesthesia in the recovery room, post-emergence 30 minutes, 60 minutes post-emergence and 6 and 24 hours post-emergence. These types of scales are commonly used to measure post operative pain both in anesthesia and in endourology
Conditions Studied
Interventions
- DRUG Bupivacaine
- OTHER Normal saline
Study Locations (1)
Illinois
- The University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2025-03-26 |
| Est. Completion | 2029-10 |
| Phase | Phase 2 |
What NCT06635889 shows while recruiting
NCT06635889 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 117-participant average among 16 other Nephrolithiasis trials with a reported enrollment target.
The record links to 1 condition, with Nephrolithiasis appearing as the primary indexed condition, and to 2 interventions - of which Bupivacaine is the first listed.
NCT06635889 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06635889 about?
NCT06635889 is a clinical study titled "Intravesical Bupivacaine on Post-Operative Ureteroscopy Pain". Post-operative pain and lower urinary tract symptoms are common following ureteroscopy in the treatment of stone disease. The use of bupivacaine as a topical pain medication is used routinely for other urologic procedures, however, to date there are no studies that have rigorously investigated the e...
What is the current status of trial NCT06635889?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2025-03-26. Estimated completion is 2029-10.
What conditions does trial NCT06635889 study?
This clinical trial studies the following conditions: Nephrolithiasis.
What interventions are being tested in trial NCT06635889?
The interventions under investigation include: Bupivacaine (DRUG), Normal saline (OTHER).
Who is sponsoring clinical trial NCT06635889?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06635889 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nephrolithiasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06635889's enrollment target sits among peer trials
116 6th of 16 higher than 10 of 16 other Nephrolithiasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Nephrolithiasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease
RECRUITING · NA
-
Thulium Fiber Laser (TFL) vs Thulio Pulsed Thulium:YAG (p-Tm:YAG)
RECRUITING · NA
-
Methocarbamol vs Oxybutynin for Management of Pain and Discomfort S/P Ureteroscopy Procedure
RECRUITING · NA
-
Gut Oxalate Absorption in Calcium Oxalate Stone Disease
RECRUITING · NA
-
Serum Endotoxin Assay to Predict the Development of Postoperative Infectious Complications and Systemic Inflammatory Response Following Percutaneous Nephrolithotomy.
RECRUITING
-
Evaluation of Genetic Abnormalities Amongst Calcium Phosphate Stone Formers
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI